Studies tumor spread in rectal cancer to guide radiation targeting
Observes how rectal cancer spreads in adults, using scans and tissue examination.
Plain-language title generated from the registry record
Registry title: DETECT: Target Volume for Rectal Endoluminal Radiation Boosting
Key facts
- Where
- Eindhoven and Maastricht, NetherlandsSee the 3 sites
Where in Netherlands
- Catharina hospitalEindhoven, NetherlandsTaking people
- Maastricht University Medical CenterMaastricht, NetherlandsTaking people
- MaastroMaastricht, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Maastricht Radiation Oncology
- Trial code
- NCT04927897
- Record updated
- 9 October 2026
- Original description
The aim of the study is to provide prospective data regarding microscopic tumor spread in all directions from the macroscopic tumor in pathology specimens, as seen by eye, and on imaging to define the target volume for endoluminal radiation boosting in rectal cancer patients.Read full original descriptionShow less
DETECT: Defining the Target Volume for Endoluminal Radiation Boosting in Patients With Rectal Cancer
The aim of the study is to provide prospective data regarding microscopic tumor spread in all directions from the macroscopic tumor in pathology specimens, as seen by eye, and on imaging to define the target volume for endoluminal radiation boosting in rectal cancer patients.
Inclusion: ≥18 years of age and capable of giving informed consent; ycT1-3N0(*) residual(**) histology confirmed rectal adenocarcinoma after neoadjuvant radiotherapy or long-course chemoradiotherapy for which patients will undergo TME surgery; Minimal interval between end of neoadjuvant chemoradiotherapy or radiotherapy: 6 weeks; (*)= as determined by clinical assessment (digital rectal examination, endoscopy with or without biopsy) and/or MRI. Biopsy/histology around the time of diagnosis is adequate; no biopsy/histology is needed after neoadjuvant therapy; (**)= including tumor regrowths/local recurrence after an initial clinical complete response and a "watch and wait" approach. These patients will also be included after the local recurrence has been determined using endoscopy and/or MRI.
Exclusion: Patient has received brachytherapy as part of neoadjuvant treatment; Patient has not been treated with neoadjuvant radiotherapy or long-course chemoradiotherapy; Patient will not undergo TME surgery for a ycT1-3N0 residual histology confirmed rectal adenocarcinoma; Interval between end of neoadjuvant therapy and surgery is <6 weeks; <18 years of age or incapable of giving informed consent.